Background: Mitochondrial trans-2-enoyl-CoA reductase (MECR) is involved in mitochondrial synthesis of fatty acids and is highly expressed in mitochondria. MECR is also known as nuclear receptor binding factor-1, which was originally reported with yeast two-hybrid screening as a binding protein of the nuclear hormone receptor peroxisome proliferator-activated receptor α (PPARα). However, MECR and PPARα are localized at different compartment, mitochondria, and the nucleus, respectively. Therefore, the presence of a cytosolic or nuclear isoform of MECR is necessary for functional interaction between MECR and PPARα. Methods: To identify the expression pattern of MECR and the cytosolic form of MECR (cMECR), we performed reverse transcription polymerase chain reaction (RT-PCR) with various tissue samples from Sprague-Dawley rats. To confirm the interaction between cMECR and PPARα, we performed several binding assays such as yeast two-hybrid, coimmunoprecipitation, and bimolecular fluorescence complementation. To observe subcellular localization of these proteins, immunocytochemistry was performed. A luciferase assay was used to measure PPARα activity. Results: We provide evidence of an alternatively spliced variant of the rat MECR gene that yields cMECR. The cMECR lacks the N-terminal 76 amino acids of MECR and shows uniform distribution in the cytoplasm and nucleus of HeLa cells. cMECR directly bound PPARα in the nucleus and increased PPARα-dependent luciferase activity in HeLa cells.
INTRODUCTION
Mammalian mitochondria perform nicotinamide adenine dinucleotide phosphate (NADPH)-dependent de novo fatty acid synthesis (FAS) [1] . This mitochondrial FAS pathway resembles the well-understood bacterial FAS II pathway [2] . Mito-chondrial trans-2-enoyl-CoA reductase (MECR) is a component of the mitochondrial FAS II pathway and catalyzes the fatty acid elongation cycle in the last step, which is the NADPHdependent reduction of the enoyl-acyl carrier protein substrate [3] [4] [5] . MECR is primarily localized in mitochondria [6] [7] [8] , and the N-terminal amino acids of this protein are important for its mitochondrial localization [9] . MECR is also known as nuclear receptor binding factor-1 (NRBF-1) because, using yeast two-hybrid screening, it was identified as a binding protein of the nuclear hormone receptor peroxisome proliferator-activated receptor α (PPARα) [10] . However, the biological meaning of the interaction between MECR and PPARα has not been determined.
PPARα is a ligand-activated transcription factor that is one of three different PPAR subtypes: PPARα, PPARβ/δ, and PPARγ. The PPARs play important roles in nutrient homeostasis [11] [12] [13] and are localized in the nucleus. Although MECR was previously reported as a binding protein of PPARα [10] , interaction between MECR and PPARα seems not to occur in mammalian cells due to their different subcellular localizations, mitochondria and the nucleus, respectively. Therefore, the presence of a cytosolic or nuclear isoform of MECR is necessary for functional interaction between MECR and PPARα in the nuclei of cells.
Here, we analyzed the expression pattern of MECR in several rat tissues and found a novel splice variant of MECR in which an additional exon was inserted between exon 1 and exon 2. The protein generated from this splicing variant has an N-terminal region that does not contain the mitochondrial targeting signal peptide and thus is not localized in mitochondria. Moreover, this MECR variant bound PPARα in the nucleus and enhanced PPARα transcriptional activity. Based on these results, we propose that this novel variant of MECR, cytosolic MECR (cMECR), plays a role in intracellular signal pathways as an interacting partner of PPARα.
METHODS
RNA extraction and reverse transcription polymerase chain reaction Total RNA was extracted from tissues of male Sprague-Dawley rats (14 weeks old) using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Total RNA (1 μg) from each sample was reverse transcribed using random primers (50 pmol), SuperScript III Reverse Transcriptase (Invitrogen), and dNTPs (1 mM) at 42°C for 1 hour. The forward primer (5′-ATGTTGGTCAGCCGGC-GACT-3′) and reverse primer (5′-TCACATAGTGAGAATCT-GCT-3′) were designed to amplify full-length MECR. Additional primers were used for specific detection of MECR and cMECR cDNA: forward primer (5′-GTGCTGGAAGCG-GCATGTTG-3′) and reverse primer (5′-TGAGCTCCAG-GTTCTTCAGT-3′). cMECR and PPARα fragments were amplified under the following cycle conditions: denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 30 seconds. This cycle was repeated 35 times. Glyceraldehyde 3-phosphate dehydrogenase fragments were also amplified under the same conditions except that 25 cycles were run. Polymerase chain reaction (PCR) products were analyzed with 2.0% agarose gel electrophoresis, purified, and ligated into the pGEM-T Easy vector (Promega, Madison, WI, USA). The recombinant plasmids were sequenced.
Construction of plasmids and antibodies
The rat full-length MECR (GenBank accession no. AB015724), cytosolic variant of MECR, and PPARα (GenBank accession no. NM_001001928) were cloned using the Gateway Cloning System (Invitrogen) as previously described [14] . After amplification of the three genes, PCR products were cloned into the pDONR207 vector and then subcloned into self-constructed destination vectors such as pDS_XB-HA, pDs_XB-Flag, pDS_ XB-enhanced green fluorescent protein (EGFP), and pDS_XB-mCherry expression vectors. Anti-Flag (F6531) antibody was purchased from Sigma (St. Louis, MO, USA). Anti-EGFP (B-2) and antihemagglutinin (anti-HA) (F-7) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture and transfection
HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin-streptomycin in a humid atmosphere containing 5% CO2 at 37°C. When needed, cells were seeded onto cover slips for imaging analysis or 60-mm dishes for preparation of lysates for Western blot analysis. Transfection of expression vectors was performed with lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. Transfected cells were cultured for an additional 24 hours in growth medium and then used for further analysis. www.e-enm.org 187 nyl fluoride, and 1% NP-40) containing a protease inhibitor cocktail (Sigma). Whole-cell lysates were incubated on ice for 30 minutes and then cleared at 13,000 rpm for 20 minutes at 4°C. The immune complexes were incubated for 1 hour at 4°C with gentle rotation with 20 μL protein A/G PLUS-agarose beads (Santa Cruz Biotechnology) that had been prewashed and suspended in 100 mL cold lysis buffer. The samples were washed three times in 1 mL cold lysis buffer and eluted in 20 μL sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. The proteins were separated with 10% SDS-PAGE and blotted onto polyvinylidene fluoride membranes. The blots were blocked with 5% skim milk in Tris-buffered saline with Tween 20 (20 mM Tris-buffered saline and 0.05% Tween 20, pH 7.5) at room temperature for 20 minutes and incubated overnight at 4°C with anti-GFP antibody (1:1,000), anti-HA antibody (1:1,000), or anti-FLAG antibody (1:1,000). Blots were then washed and incubated with horseradish peroxidase-conjugated secondary antibody (1: 3,000), followed by washing and detection of immunoreactivity with enhanced chemiluminescence (Amersham, Piscataway, NJ, USA).
Coimmunoprecipitation and Western blot analysis

Imaging analysis
Subcellular distribution of MECR, cMECR, and PPARα were confirmed according to the EGFP and mCherry fluorescence detection method with a confocal microscope (Olympus Fluoview FV1000, Olympus, Tokyo, Japan). For imaging analysis, cells were plated onto glass cover slips. After transfection, the cells were grown for 24 hours and treated with the mitochondrion-selective fluorescent dye mito-tracker red CMXRos (Molecular Probes Europe BV, Leiden, Netherlands) according to the manufacturer's instructions.
Yeast two-hybrid assay cMECR was cloned into pGADT7 encoding the activation domain, and PPARα was ligated into pGBKT7 encoding the GAL4 DNA binding domain. To evaluate the protein-protein interaction between cMECR and PPARα, both pGAD-cMECR and pGBK-PPARα were cotransformed into the yeast strain AH109. This strain is unable to synthesize histidine. However, interaction between cMECR and PPARα enables the yeast to make the His3 enzyme, thereby permitting histidine biosynthesis and growth on His minimal medium.
Bimolecular fluorescence complementation assays
C-and N-terminal venus plasmids were purchased from Addgene and modified to contain cMECR or PPARα with subcloning. Cells were transfected with the lipofectamine 2000 reagent (Invitrogen) with venus plasmids containing cMECR and PPARα. After 24 hours, cells were imaged with confocal microscopy as described above.
Luciferase assay
HeLa cells were plated at a density of 1.0 to 1.5×10 5 
RESULTS
Identification of a novel alternative transcript variant of MECR
During reverse transcription (RT)-PCR analysis of MECR expression in the rat brain, two different MECR transcripts were detected. One was the expected MECR mRNA (210 bp), which corresponds to the known MECR mRNA (GenBank accession no. AB015724). The other was a longer 306-bp PCR fragment (Fig. 1C) . Because PCR was carried out with specific primers corresponding to exons 1 and 2 of rat MECR cDNA, alternative splicing was proposed to account for the presence of this fragment. Fig. 1A shows the 10 exons of rat MECR cDNA. The novel MECR variant has an additional 96 nucleotides between exon 1 and exon 2. Basic local alignment search tool analysis of the aligned sequences of rat genomic DNA (chromosome 5 genomic contig NW_047784) and cDNA of this MECR variant showed that the flanking nucleotides of convergent points between exon 1 and exon 2 followed the GT/AG rule of alternative splicing ( Supplementary Fig. 1A ). This addition of 96 nucleotides generated a frame-shifted MECR, and the N-terminal 76 amino acids were deleted by use of another start codon in exon 3 ( Next, to compare expression of cMECR and MECR, RT-PCR analyses were done using RNA samples from eight different tissues with a specific primer set as shown in Fig. 1B . As shown in Fig. 1C , cMECR (306 bp) and MECR (210 bp) were ubiquitously expressed in most tissues examined, although the expression level of cMECR was lower than that of MECR. Furthermore, we found amino acid sequences of human MECR isoform 2 (GenBank accession no. NP001019903.1) were well matched with that of rat cMECR (Supplementary Fig. 1B ). These data raise the possibility that cMECR can be produced in other species.
cMECR localized in the cytoplasm and nucleus of HeLa cells
To visualize the intracellular distribution of MECR in HEK cells, we generated two constructs containing EGFP-tagged full-length rat MECR. As shown in Supplementary Fig. 2 , when EGFP was tagged to the C-terminal end of MECR (MECR-EGFP), this protein was distinctly expressed in mitochondria, as previously reported [3] . However, the N-terminal EGFP-tagged MECR (EGFP-MECR) was diffusely expressed in the cytoplasm of HEK cells. N-terminal tagging of the protein with EGFP might have disrupted the proper mitochondrial localization of MECR, perhaps because the N-terminal mitochondrial targeting sequence of MECR was masked by the EGFP. These results suggest that N-terminal mitochondrial targeting sequences are critical for mitochondrial localization of MECR proteins.
Because cMECR lacks the N-terminal mitochondrial targeting sequences, the intracellular distribution of this protein was unclear. The intracellular distribution of MECR and cMECR was thus compared by tagging both cDNAs with EGFP at their C-terminal ends and then transiently expressing them in HeLa cells (Fig. 2) . MECR-EGFP showed a well-defined punctate pattern that clearly colocalized with mito tracker, a marker of mitochondria (Fig. 2B) . However, cMECR-EGFP was expressed in cytosolic and nuclear regions and did not colocalize with Mito tracker (Fig. 2C) . Copyright © 2014 Korean Endocrine Society cMECR directly interacts with PPARα MECR, also known as NRBF-1, was previously identified with yeast two-hybrid screening as a PPARα-interacting protein [10] , although explaining how mitochondrial-targeted MECR interacted with the nuclear hormone receptor PPARα was difficult. In contrast to MECR, cMECR was localized in the cytoplasm and nucleus of HeLa cells, and its amino acid sequence is exactly the same as that of MECR, except for the N-terminal 76 amino acids that compose the mitochondrial targeting sequence. Thus, cMECR, rather than mitochondrial MECR, could interact with PPARα in the nucleus. Indeed, the yeast two-hybrid assay showed a direct interaction between cMECR and PPARα (Fig. 3A) . Immunoprecipitation and colocalization analyses also showed that cMECR interacted with PPARα in HeLa cells (Fig. 3B) . Furthermore, cMECR-EGFP colocalized with mCherry-tagged PPARα in the nucleus of HeLa cells (Fig. 3C) . In contrast, wild-type MECR was not colocalized with PPARα in HeLa cells (Supplementary Fig. 3 ). Taken together, these data strongly indicate that cMECR, but not MECR, is a bona fide binding partner of PPARα. calization analyses, the BiFC experiment also indicated protein-protein interaction between cMECR and PPARα (Fig.  4B ). Only when both constructs were cotransfected was the BiFC signal seen in the nucleus of HeLa cells. Individual con-MECR-EGFP mCherry-PPARα Merge Supplementary Fig. 3 . Localization of mitochondrial trans-2-enoyl-CoA reductase (MECR) and peroxisome proliferator-activated receptor α (PPARα): wild-type MECR is localized in cytosolic regions, whereas PPARα is localized in nuclear regions. HeLa cells were transiently transfected with MECR-enhanced green fluorescent protein (EGFP; green) and mCherry-PPARα (red). Scale bar=20 μm.
cells [15, 16] . We constructed the N-terminal part of venus plasmids tagged to cMECR (cMECR-VN) and the C-terminal portion of venus plasmids tagged to PPARα (VC-PPARα) (Fig. 4A) . Consistent with the immunoprecipitation and colo-Copyright © 2014 Korean Endocrine Society
DISCUSSION
MECR has been reported to be a mitochondrial protein [7] that catalyzes NADPH-dependent reduction of trans-2-enoyl thioesters to the corresponding saturated acyl thioesters [5] . However, NRBF-1 (also known as MECR) was originally identified as a binding protein of the nuclear receptor PPARα [10] . In that paper, the authors did not perform any assessment of endogenous binding in cells or report the biological meaning of this protein-protein interaction, although NRBF-1 binds with PPARα in the yeast two-hybrid system. Here, we report a cMECR that is generated by alternative splicing. cMECR is an N-terminal-76-amino-acid truncated structs (cMECR-VN or VC-PPARα) did not produce fluorescence alone (Fig. 4B) . These results imply that cMECR interacts with PPARα in the nucleus of HeLa cells. cMECR interacts with PPARα, a well-known nuclear hormone receptor. Thus, to examine whether cMECR can modulate PPARα activity, we transfected cMECR into HeLa cells together with PPARα and a luciferase reporter plasmid containing a PPAR-binding site (Fig. 4C) . Compared with cells transfected with PPARα only, PPAR-dependent luciferase expression levels were significantly increased in the presence of cMECR. These results indicate that cMECR can act as a coactivator of PPARα in the nucleus of HeLa cells. isoform of MECR. Because mitochondrial targeting signal sequences are contained between amino acids 1 and 53 of MECR [8] , cMECR lacks this mitochondrial targeting signal sequence and was preferentially localizes to cytosolic and nuclear regions and was not present in mitochondria (Fig. 2C) . In addition, our data show that N-terminal EGFP-tagged MECR also lost its proper intracellular localization (Supplementary Fig. 2) . Therefore, the N-terminal region of MECR is critical for mitochondrial localization of the MECR protein.
Different intracellular distribution of cMECR strongly implies that its biological functions differ from the functions of MECR. In addition, cMECR mRNA was ubiquitously expressed in eight tested tissues (Fig. 1C) , implying that cMECR could perform common essential functions in the various tissues. Although further studies should be performed to elucidate the function(s) of cMECR, we present its first function in this study. Various nuclear receptors activate transcription of their target genes through interactions with coactivators or corepressors [17, 18] . Like other coactivators, cMECR directly bound PPARα in the nucleus and potentiated PPARα activity (Fig. 4) .
Generally, PPARα is found in tissues where fatty acid metabolism is important and regulates genes involved in lipid and lipoprotein metabolism as well as glucose homeostasis [19] [20] [21] . Because cMECR potentiates PPARα activity in HeLa cells, cMECR could be involved in these biological phenomena. An earlier study used the yeast two-hybrid assay and demonstrated that MECR (NRBF-1) also interacts with various nuclear hormone receptors such as TRβ, RARα, RXRα, and HNF-4 [10] . Because our data strongly support the idea that cMECR is a bona fide binding partner of PPARα and its amino acid sequence is the same as that of MECR except that it lacks the N-terminal 76 amino acids, cMECR might also bind with other nuclear hormone receptors. This possibility should be tested in future studies.
In summary, our results suggest that cMECR, a novel alternatively spliced variant of MECR, directly interacts with PPARα in the nucleus and could be a positive regulator in the physiological regulation of PPARα.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
